Pharmaceutical

Novartis signs deal for Arvinas’ prostate cancer therapy

Novartis has signed an exclusive strategic licence agreement for Arvinas’ ARV-766, a new treatment for prostate cancer.

Apr 13, 2024 - 00:00
Novartis signs deal for Arvinas’ prostate cancer therapy
Novartis has signed an exclusive strategic licence agreement for Arvinas’ ARV-766, a new treatment for prostate cancer.
Read the original article

Tags:

Previous Article

Eliem Therapeutics agrees to acquire Tenet

Next Article

FDA approves AstraZeneca’s FASENRA for asthma in children

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

MHRA agrees licence change for Pfizer-BioNTech’s Comirnaty vaccine

MHRA agrees licence change for Pfizer-BioNTech’s Comirn...

Feb 12, 2024

Merck’s net income for Q1 2024 increases by 69% to $4.76bn

Merck’s net income for Q1 2024 increases by 69% to $4.76bn

Apr 27, 2024

ARS Pharmaceuticals’ anaphylaxis nasal spray gains FDA approval

ARS Pharmaceuticals’ anaphylaxis nasal spray gains FDA ...

Aug 13, 2024